

NEWS RELEASE

Media Relations Contacts:

Len Hall

Allen & Caron, Inc.

(949) 474-4300

len@allencaron.com

Investor Relations Contact:

Matt Clawson or Dan Matsui

Allen & Caron, Inc.

(949) 474-4300

matt@allencaron.com

BIOLIFE SOLUTIONS FORMS SCIENTIFIC ADVISORY BOARD

*LEADING CANCER THERAPY RESEARCHER, CRYOPRESERVATION RESEARCHER, AND
REGULATORY EXPERT JOIN AS FOUNDING OUTSIDE MEMBERS*

OWEGO, N.Y., Oct. 4 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS), a leading marketer of proprietary, serum and protein free hypothermic storage and cryopreservation solutions for cells and tissue at low temperatures, announced today it has formed a Scientific Advisory Board to be comprised of leading researchers, scientists and consultants to help guide and counsel the Company as it develops products for its core markets including biotechnology, cellular therapy, tissue engineering, and organ transplantation.

BioLife's Scientific Advisory Board will be led by John G. Baust, Ph.D., the Company's founder, Chairman and Chief Scientific Officer. Additional members will be added throughout the remainder of the year.

The founding outside members are:

- Shelly Heimfeld, Ph.D., Director of the Cellular Therapy Laboratory at the Fred Hutchinson Cancer Research Center in Seattle, and President of the International Society of Cellular Therapy. Dr. Heimfeld is internationally recognized for research in hematopoietic-derived stem cells and the development of cell processing technologies for improved cancer therapy.
- Dayong Gao, Ph.D., professor of biomedical engineering at the University of Washington in Seattle. Dr. Gao has been actively engaged in cryopreservation research for more than 20 years, having authored over 130 peer-reviewed journal articles on cryopreservation.
- Darin Weber, Ph.D., a leading regulatory expert for cellular and tissue based products, and former FDA cellular therapy reviewer. Dr. Weber's knowledge of the regulatory landscape for cell and gene therapy is extensive and directly relevant to BioLife's business since the Company's preservation solutions are a critical process component in several active clinical trials for new cellular therapy products.



Mike Rice, CEO of BioLife Solutions, commented, "We are extremely pleased to have scientists and experts of the caliber of Dr.'s Heimfeld, Gao and Weber join our Scientific Advisory Board. We look forward to leveraging their collective experience as we continue to expand the unique capabilities of our products."

Dr. Heimfeld stated, "The cell therapy industry is very cognizant of the problems associated with the quality of cells derived using traditional preservation protocols. We expect to work closely with BioLife to validate a new generation of cell preservation technologies that will address those concerns and enhance our ability to deliver effective cell-based therapy to our patients."

Dr. Gao noted, "The science underlying BioLife's products is truly innovative, and represents the first significant advance in cryopreservation technologies in more than 50 years. The BioLife team pioneered a superior molecular approach to inhibiting apoptosis and necrosis in preserved cells and tissues. Its products offer clear advantages of improved post-thaw yield and cellular function."

Dr. Weber also added, "Companies engaged in cellular therapy research and development must follow strict protocols to ensure the quality of all system components and process steps. BioLife's cryopreservation products represent a key enabling technology for 'off the shelf' availability of cellular therapies. I look forward to serving on BioLife's Scientific Advisory Board to identify new opportunities to better serve its customers who need cryopreservation solutions that meet regulatory requirements."

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) preservation media are marketed directly to companies, laboratories, and academic institutions engaged in research and commercial clinical applications. BioLife's line of serum-free and protein-free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function. For more information please visit BioLife Solutions' website at <http://www.biolifesolutions.com>.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific



factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

###